NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
NYSE:NMR - New York Stock Exchange, Inc. - US65535H2085 - ADR
We assign a fundamental rating of 4 out of 10 to NMR. NMR was compared to 224 industry peers in the Capital Markets industry. NMR may be in some trouble as it scores bad on both profitability and health. NMR is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! NMR also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year NMR was profitable.
NMR had a negative operating cash flow in the past year.
NMR had positive earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of 0.48%, NMR is not doing good in the industry: 73.97% of the companies in the same industry are doing better.
NMR has a Return On Equity of 8.32%. This is comparable to the rest of the industry: NMR outperforms 48.86% of its industry peers.
With a Return On Invested Capital value of 0.49%, NMR is not doing good in the industry: 79.00% of the companies in the same industry are doing better.
The Average Return On Invested Capital over the past 3 years for NMR is significantly below the industry average of 6.66%.
The last Return On Invested Capital (0.49%) for NMR is above the 3 year average (0.31%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.48% | ||
| ROE | 8.32% | ||
| ROIC | 0.49% |
ROA(3y)0.27%
ROA(5y)0.34%
ROE(3y)4.27%
ROE(5y)5.33%
ROIC(3y)0.31%
ROIC(5y)0.34%
1.3 Margins
NMR has a Profit Margin of 5.83%. This is in the lower half of the industry: NMR underperforms 67.58% of its industry peers.
In the last couple of years the Profit Margin of NMR has declined.
NMR has a worse Operating Margin (8.63%) than 71.69% of its industry peers.
In the last couple of years the Operating Margin of NMR has declined.
With a Gross Margin value of 37.85%, NMR is not doing good in the industry: 68.95% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of NMR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.63% | ||
| PM (TTM) | 5.83% | ||
| GM | 37.85% |
OM growth 3Y-22.7%
OM growth 5YN/A
PM growth 3Y-25.03%
PM growth 5YN/A
GM growth 3Y-24.32%
GM growth 5Y-9.19%
2. Health
2.1 Basic Checks
The number of shares outstanding for NMR has been reduced compared to 1 year ago.
Compared to 5 years ago, NMR has less shares outstanding
The debt/assets ratio for NMR is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.30, we must say that NMR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.30, NMR is doing worse than 86.76% of the companies in the same industry.
NMR has a Debt/Equity ratio of 11.22. This is a high value indicating a heavy dependency on external financing.
NMR's Debt to Equity ratio of 11.22 is on the low side compared to the rest of the industry. NMR is outperformed by 91.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 11.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.3 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.23 indicates that NMR may have some problems paying its short term obligations.
The Current ratio of NMR (0.23) is worse than 82.19% of its industry peers.
NMR has a Quick Ratio of 0.23. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NMR (0.23) is worse than 82.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 108.95% over the past year.
NMR shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.74% yearly.
Looking at the last year, NMR shows a very strong growth in Revenue. The Revenue has grown by 36.58%.
NMR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.77% yearly.
EPS 1Y (TTM)108.95%
EPS 3Y2.74%
EPS 5YN/A
EPS Q2Q%189%
Revenue 1Y (TTM)36.58%
Revenue growth 3Y36.99%
Revenue growth 5Y17.77%
Sales Q2Q%25.89%
3.2 Future
Based on estimates for the next years, NMR will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.98% on average per year.
NMR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.13% yearly.
EPS Next Y56.17%
EPS Next 2Y27.22%
EPS Next 3Y18.98%
EPS Next 5YN/A
Revenue Next Year46.01%
Revenue Next 2Y20.18%
Revenue Next 3Y13.13%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.31, the valuation of NMR can be described as very reasonable.
Based on the Price/Earnings ratio, NMR is valued a bit cheaper than the industry average as 67.58% of the companies are valued more expensively.
NMR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.94.
Based on the Price/Forward Earnings ratio of 10.16, the valuation of NMR can be described as reasonable.
Based on the Price/Forward Earnings ratio, NMR is valued a bit cheaper than 68.49% of the companies in the same industry.
NMR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.11.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.31 | ||
| Fwd PE | 10.16 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NMR is valued a bit cheaper than 66.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 23.4 |
4.3 Compensation for Growth
NMR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NMR's earnings are expected to grow with 18.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.18
PEG (5Y)N/A
EPS Next 2Y27.22%
EPS Next 3Y18.98%
5. Dividend
5.1 Amount
NMR has a Yearly Dividend Yield of 4.14%, which is a nice return.
Compared to an average industry Dividend Yield of 9.45, NMR has a dividend in line with its industry peers.
NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 2.28.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.14% |
5.2 History
On average, the dividend of NMR grows each year by 7.29%, which is quite nice.
NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
NMR has decreased its dividend in the last 3 years.
Dividend Growth(5Y)7.29%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
25.01% of the earnings are spent on dividend by NMR. This is a low number and sustainable payout ratio.
NMR's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.01%
EPS Next 2Y27.22%
EPS Next 3Y18.98%
NOMURA HOLDINGS INC-SPON ADR
NYSE:NMR (1/17/2025, 8:17:43 PM)
After market: 5.98 0 (0%)5.98
+0.1 (+1.7%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners36.33%
Inst Owner Change-0.24%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.67B
Analysts69.23
Price Target6.54 (9.36%)
Short Float %0.01%
Short Ratio0.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.14% |
Yearly Dividend20.14
Dividend Growth(5Y)7.29%
DP25.01%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.02%
PT rev (3m)3.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)26.32%
Revenue NY rev (3m)26.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.31 | ||
| Fwd PE | 10.16 | ||
| P/S | 0.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.84 | ||
| P/tB | 0.85 | ||
| EV/EBITDA | 23.4 |
EPS(TTM)0.58
EY9.7%
EPS(NY)0.59
Fwd EY9.84%
FCF(TTM)-2.77
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS10.19
BVpS7.14
TBVpS7.07
PEG (NY)0.18
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.48% | ||
| ROE | 8.32% | ||
| ROCE | 1.45% | ||
| ROIC | 0.49% | ||
| ROICexc | 0.54% | ||
| ROICexgc | 0.55% | ||
| OM | 8.63% | ||
| PM (TTM) | 5.83% | ||
| GM | 37.85% | ||
| FCFM | N/A |
ROA(3y)0.27%
ROA(5y)0.34%
ROE(3y)4.27%
ROE(5y)5.33%
ROIC(3y)0.31%
ROIC(5y)0.34%
ROICexc(3y)0.34%
ROICexc(5y)0.37%
ROICexgc(3y)0.34%
ROICexgc(5y)0.38%
ROCE(3y)0.89%
ROCE(5y)1.01%
ROICexcg growth 3Y-3.29%
ROICexcg growth 5YN/A
ROICexc growth 3Y-3.32%
ROICexc growth 5YN/A
OM growth 3Y-22.7%
OM growth 5YN/A
PM growth 3Y-25.03%
PM growth 5YN/A
GM growth 3Y-24.32%
GM growth 5Y-9.19%
F-Score5
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 11.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 78.89 | ||
| Cap/Depr | 1824.53% | ||
| Cap/Sales | 24.27% | ||
| Interest Coverage | 0.14 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 | ||
| Altman-Z | -0.3 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)580.51%
Cap/Depr(5y)450.89%
Cap/Sales(3y)10.9%
Cap/Sales(5y)10.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.95%
EPS 3Y2.74%
EPS 5YN/A
EPS Q2Q%189%
EPS Next Y56.17%
EPS Next 2Y27.22%
EPS Next 3Y18.98%
EPS Next 5YN/A
Revenue 1Y (TTM)36.58%
Revenue growth 3Y36.99%
Revenue growth 5Y17.77%
Sales Q2Q%25.89%
Revenue Next Year46.01%
Revenue Next 2Y20.18%
Revenue Next 3Y13.13%
Revenue Next 5YN/A
EBIT growth 1Y94.33%
EBIT growth 3Y5.89%
EBIT growth 5YN/A
EBIT Next Year35370.4%
EBIT Next 3Y618.31%
EBIT Next 5YN/A
FCF growth 1Y33.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.55%
OCF growth 3Y-49.33%
OCF growth 5YN/A